Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06815471 · Corteria Pharmaceuticals

CRF2 Agonist for the Treatment of Worsening Heart Failure

(CRAFT-WHF)

What this study is about

This study assesses the effects of the experimental drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

View original scientific description

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Interventions

DRUG

COR-1167

28-day treatment

DRUG

Placebo

28-day treatment

Primary outcome measures

Natriuresis

Time frame: 24 hours

Urinary sodium excretion

Body weight

Time frame: 7 days

Changes in body weight

NT-proBNP

Time frame: 7 days

Changes in NT-proBNP

Kansas City Cardiomyopathy Questionnaire (KCCQ)-Total Symptom Score (TSS)

Time frame: 28 days

Changes in KCCQ-TSS - The score ranges from 0 to 100 with higher score indicating a better health status

Left Atrial Volume index (LAVi)

Time frame: 2 days

Changes in LAVi - LAV-i is an index of cardiac function measured by echocardiogram

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Signed written informed consent
  • Previous diagnosis of HF documented in source records and confirmed by investigator assessment (no historical written documentation required)
  • Prescribed an oral loop diuretic for at least 1 month preceding the index event
  • NT-proBNP ≥300 pg/mL or BNP ≥100 pg/mL
  • Requires treatment with i.v. diuretics for volume overload
  • At least 1 risk factor for diuretic resistance
  • Admitted to the hospital not more than 120 hours prior to randomization

Exclusion criteria

  • Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia)
  • Administration of i.v. inotropic therapy or i.v. vasodilators, use of mechanical ventilation, high-flow oxygen therapy, or NIV prior to randomization
  • Requirement for, or planned use of LVADs, IABP, or any type of MCS
  • History of solid organ transplant or active on a transplant list
  • SBP \<100 mmHg
  • eGFR \< 20 mL/min/1.73 m2
  • CABG, PCI, implantation of CRT, heart valve procedure or any cardiac surgery within 1 month prior to screening or planned during the study
  • Severe stenotic cardiac valvular disease
  • Severe chronic pulmonary disease requiring chronic steroid therapy or chronic oxygen therapy (\> 2 L/min)
  • Uncorrected severe hyperthyroidism or hypothyroidism
  • Severe restrictive, obstructive, or infiltrative cardiomyopathy
  • Body weight \< 70 kg at screening
  • Use of any investigational drug(s) within 5 half-lives of screening
  • At high risk of death, defined as life expectancy ≤1 year (such as participants in potential impending cardiogenic shock), or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult
  • Presence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures
  • Participant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
  • Increased lactate levels \> upper limit of normal (local laboratory) at screening
  • Severe chronic liver disease (such as cirrhosis)

Where

  • Indianapolis, Indiana
  • Detroit, Michigan
  • Greensboro, North Carolina
  • Raleigh, North Carolina
  • Columbus, Ohio
  • Oklahoma City, Oklahoma

Collaborators

Worldwide Clinical Trials

Related conditions & keywords

Worsening Heart FailureCOR-1167Hospitalised heart failureWHF

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Nov 16, 2026 · Source of record for eligibility and locations

📊
1 of 210 participants interested
0% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

ACTIVE_NOT_RECRUITING

Indianapolis

Indiana

Location available
ACTIVE_NOT_RECRUITING

Detroit

Michigan

Location available
ACTIVE_NOT_RECRUITING

Detroit

Michigan

Location available
ACTIVE_NOT_RECRUITING

Greensboro

North Carolina

Location available
RECRUITING

Raleigh

North Carolina

Location available
RECRUITING

Columbus

Ohio

Location available
WITHDRAWN

Oklahoma City

Oklahoma

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Heart Failure Trials by City

Browse all heart failure clinical trials in these cities — not just this study.

Looking for Worsening Heart Failure Treatment in Indianapolis?

Join others in Indiana exploring innovative treatment options through clinical research

Worsening Heart Failure Treatment Options in Indianapolis, Indiana

If you're searching for Worsening Heart Failure treatment in Indianapolis, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Indianapolis, Detroit, Greensboro and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Worsening Heart Failure. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Indiana
Now Enrolling
Up to 210 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Worsening Heart Failure?

Potential Benefits

  • ✓Access to new treatment approaches before public availability
  • ✓Close monitoring by experienced medical professionals
  • ✓Study-related care provided at no cost
  • ✓Contribute to medical research for Worsening Heart Failure

What to Expect

  • →Initial screening to determine eligibility
  • →Regular check-ups and monitoring visits
  • →Possible compensation for time and travel
  • →You can withdraw at any time

Frequently Asked Questions About This Worsening Heart Failure Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06815471. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.